Top

Published in:

01-10-2003 | Review

The aging spine: new technologies and therapeutics for the osteoporotic spine

Authors: Joseph M. Lane, Michael J. Gardner, Julie T. Lin, Marjolein C. van der Meulen, Elizabeth Myers

Published in: European Spine Journal | Special Issue 2/2003

Abstract

Osteoporosis results in low-energy fractures of the spine. The load necessary to cause a vertebral fracture is determined by the characteristics related to the vertebral body structure, mineral content, and quality of bone. Radiographic techniques centered on dual X-ray absorptiometry (DXA) permit a determination of bone mass and fracture risk. Current medical therapies principally using bisphosphonate and pulsatile PTH profoundly decrease the risk of fracture (50+%). Fall prevention strategies can further decrease the possibility of fracture. A comprehensive approach to osteoporosis can favorably alter the disease.

Adami S, Prizzi R, Colapietro F (2001). Alendronate for the treatment of osteoporosis in men. Calcif Tissue Int 69:239–241CrossRefPubMed

Arnaud CD (1996) Osteoporosis: using ‘bone markers’ for diagnosis and monitoring. Geriatrics 51:24–30

Bagur A, Solis F, Di Gregorio S, Mautalen C (2000) Reference data of vertebral morphometry by X-ray absorptiometry (MXA) in Argentine women. Calcif Tissue Int 66:259–262CrossRefPubMed

Baylink DJ (2000) The diagnosis and management of osteoporosis. J Rheumatol 59 [Suppl 1]:42–44

Bianco AC, Malvestiti LF, Gouveia CH, Wehba S, Lewin S, Marone MM (1999) Morphometric dual-energy X-ray absorptiometry of the spine: report of a large series and correlation with axial bone mineral density. J Bone Miner Res 14:1605–1613PubMed

Bidwell J, Feister H, Swartz D, Onyia J, Holden J, Hock J (1996) Parathyroid hormone regulates the expression of rat osteoblast and osteosarcoma nuclear matrix proteins. J Cell Biochem 63:374–383PubMed

Black DM, Cummings SR, Karpf DB, et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535–1541PubMed

Body JJ, Gaich GA, Scheele WH, et al (2002) A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1–34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 87:4528–4535CrossRefPubMed

Carter DR, Hayes WC (1977) The compressive behavior of bone as a two-phase porous structure J Bone Joint Surg Am 59:954–962

10.

Carter DR, Bouxsein ML, Marcus R (1992) New approaches for interpreting projected bone densitometry data. J Bone Miner Res 7:137–145PubMed

11.

Cauley JA, Thompson DE, Ensrud KC, Scott JC, Black D (2000) Risk of mortality following clinical fractures. Osteoporos Int 11:556–561CrossRefPubMed

12.

Cauley JA, Norton L, Lippman ME, et al (2001) Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 65:125–134CrossRefPubMed

13.

Chausmer AB (2001) Bone density measurement techniques in the diagnosis and management of osteoporosi. J S C Med Assoc 97:106–110PubMed

14.

Chavassieux PM, Arlot ME, Roux JP, et al (2000) Effects of alendronate on bone quality and remodeling in glucocorticoid-induced osteoporosis: a histomorphometric analysis of transiliac biopsies. J Bone Miner Res 15:754–762PubMed

15.

Chestnut CH 3rd, Silverman S, Adriano K, Genant H (2002) A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the Prevent Recurrence of Osteoporotic Fractures Study. PROOF Study Group. Am J Med 109:267–276CrossRef

16.

Cooper C (1997) The crippling consequences of fractures and their impact on quality of life. Am J Med 103:12S-17S; discussion 17S-19S

17.

Crandall C (2002) Parathyroid hormone for treatment of osteoporosis. Arch Intern Med 162:2297–2309CrossRefPubMed

18.

Cummings SR, Black DM, Thompson DE, et al (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280:2077–2082PubMed

19.

Dawson-Hughes B, Harris SS, Krall EA, Dallal GE (1997) Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 337:670–676

20.

Delmas PD, Ensrud KE, Adachi JD, et al (2002) Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 87:3609–3617

21.

Dickler MN, Norton L (2001) The MORE trial: multiple outcomes for raloxifene evaluation—breast cancer as a secondary end point: implications for prevention. Ann N Y Acad Sci 949:134–142PubMed

22.

Doggrell SA (2002) Zoledronate once-yearly increases bone mineral density — implications for osteoporosis. Expert Opin Pharmacother 3:1007–1009PubMed

23.

Ensrud KE, Thompson DE, Cauley JA, et al (2000) Prevalent vertebral deformities predict mortality and hospitalization in older women with low bone mass. Fracture Intervention Trial Research Group. J Am Geriatr Soc 48:241–249PubMed

24.

Ettinger B, Black DM, Mitlak BH, et al (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282:637–645PubMed

25.

Ferrar L, Jiang G, Barrington NA, Eastell R (2000) Identification of vertebral deformities in women: comparison of radiological assessment and quantitative morphometry using morphometric radiography and morphometric X-ray absorptiometry. J Bone Miner Res 15:575–585PubMed

26.

Ferrar L, Jiang G, Eastell R (2001) Longitudinal evaluation of morphometric X-ray absorptiometry for the identification of vertebral deformities. Osteoporos Int 12:661–671CrossRefPubMed

27.

Finkelstein JS, Klibanski A, Arnold AL, Toth TL, Hornstein MD, Neer RM (1998) Prevention of estrogen deficiency-related bone loss with human parathyroid hormone-(1–34): a randomized controlled trial. JAMA 280:1067–1073CrossRefPubMed

28.

Follin SL, Black JN, McDermott MT (2003) Lack of diagnosis and treatment of osteoporosis in men and women after hip fracture. Pharmacotherapy 23:190–198PubMed

29.

Fujita T, Inoue T, Morii H, et al (1999) Effect of an intermittent weekly dose of human parathyroid hormone (1–34) on osteoporosis: a randomized double-masked prospective study using three dose levels. Osteoporos Int 9:296–306CrossRefPubMed

30.

Galante J, Rostoker W, Ray RD (1970) Physical properties of trabecular bone. Calcif Tis Res 5:236–246

31.

Gardner MJ, Flik KR, Mooar P, Lane JM (2002) Improvement in the undertreatment of osteoporosis following hip fracture. J Bone Joint Surg Am 84:1342–1348

32.

Gass R (2001) The early preclinical diagnosis of osteoporosis measuring the pure trabecular bone density. Eur J Med Res 6:228–230PubMed

33.

Geusens P, Autier P, Boonen S, Vanhoof J, Declerck K, Raus JN (2002) The relationship among history of falls, osteoporosis, and fractures in postmenopausal women. Arch Phys Med Rehabil 83:903–906CrossRefPubMed

34.

Giannoukos G, Williams LJ, Chilco PJ, Abou-Samra AB (1999) Characterization of an element within the rat parathyroid hormone/parathyroid hormone-related peptide receptor gene promoter that enhances expression in osteoblastic osteosarcoma 17/2.8 cells. Biochem Biophys Res Commun 258:336–340CrossRefPubMed

35.

Gonnelli S, Cepollaro C, Montagnani A, et al (2003) Alendronate treatment in men with primary osteoporosis: a three-year longitudinal study. Calcif Tissue Int

36.

Grados F, Fardellone P, Benammar M, Muller C, Roux C, Sebert JL (1999) Influence of age and sex on vertebral shape indices assessed by radiographic morphometry. Osteoporos Int 10:450–455CrossRefPubMed

37.

Greenspan SL, von Stetten E, Emond SK, Jones L, Parker RA (2001) Instant vertebral assessment: a noninvasive dual X-ray absorptiometry technique to avoid misclassification and clinical mismanagement of osteoporosis. J Clin Densitom 4:373–380PubMed

38.

Greenspan SL, Bone G 3rd, Schnitzer TJ, et al (2002) Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis. J Bone Miner Res 17:1988–1996PubMed

39.

Guermazi A, Mohr A, Grigorian M, Taouli B, Genant HK (2002) Identification of vertebral fractures in osteoporosis. Sem Musculoskeletal Radiol 6:241–252CrossRef

40.

Harris ST, Watts NB, Genant HK, et al (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282:1344–1352PubMed

41.

Hasserius R, Karlsson MK, Nilsson BE, Redlund-Johnell I, Johnell O (2003) Prevalent vertebral deformities predict increased mortality and increased fracture rate in both men and women: a 10-year population-based study of 598 individuals from the Swedish cohort in the European Vertebral Osteoporosis Study. Osteoporos Int 14:61–68PubMed

42.

Hayes WC, Myers ER, Robinovitch SN, van den Kroonenberg A, Courtney A, McMahon T (1996) Etiology and prevention of age-related hip fractures

43.

Heijckmann AC, Juttmann JR, Wolffenbuttel BH (2002) Intravenous pamidronate compared with oral alendronate for the treatment of postmenopausal osteoporosis. Neth J Med 60:315–319PubMed

44.

Holzer G, Majeska RJ, Lundy MW, Hartke JR, Einhorn TA (1999) Parathyroid hormone enhances fracture healing. A preliminary report. Clin Orthop 258–263

45.

Horwitz MJ, Tedesco MB, Gundberg C, Garcia-Ocana A, Stewart AF (2003) Short-term, high-dose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 88:569–575CrossRefPubMed

46.

Ito M, Tsurusaki K, Hayashi K (1997) Peripheral QCT for the diagnosis of osteoporosis. Osteoporos Int 7 [Suppl 3]:120–127

47.

Jahng JS, Kim HW (2000) Effect of intermittent administration of parathyroid hormone on fracture healing in ovariectomized rats. Orthopedics 23:1089–1094PubMed

48.

Jalava T, Sarna S, Pylkkanen L, et al (2003) Association between vertebral fracture and increased mortality in osteoporotic patients. J Bone Miner Res 18:1254–1260PubMed

49.

Jordan KM, Cooper C (2002) Epidemiology of osteoporosis Best Pract Res Clin Rheumatol 16:795–806CrossRef

50.

Kado DM, Duong T, Stone KL, Ensrud KE, et al (2003) Incident vertebral fractures and mortality in older women: a prospective study. Osteoporosis Int 14:589–594

51.

Kanis JA (2002) Diagnosis of osteoporosis and assessment of fracture risk. Lancet 359:1929–1936CrossRefPubMed

52.

Kelly CM, Wilkins RM, Gitelis S, Hartjen C, Watson JT, Kim PT (2001) The use of a surgical grade calcium sulfate as a bone graft substitute: results of a multicenter trial. Clin Orthop 42–50

53.

Kessenich CR (1998) Tai Chi as a method of fall prevention in the elderly. Orthop Nurs 17:27–29

54.

Lane JM (1997) Osteoporosis. Medical prevention and treatment. Spine 22:32S-37SCrossRefPubMed

55.

Lane JM, Nydick M (1999) Osteoporosis: current modes of prevention and treatment. J Am Acad Orthop Surg 7:19–31PubMed

56.

Lieberman JR, Le LQ, Wu L, et al (1998) Regional gene therapy with a BMP-2-producing murine stromal cell line induces heterotopic and orthotopic bone formation in rodents. J Orthop Res 16:330–339PubMed

57.

Liberman UA, Weiss SR, Broll J, et al (1995) Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 333:1437–1443PubMed

58.

Lin JT, van der Meulen MCH, Myers ER, Lane JM (2003) Fracture evaluation and clinical complications. In: Favus MJ (ed) Primer on the metabolic bone diseases and disorders of mineral metabolism, 5th edn. (in press)

59.

Lin JT, Backus S, Meyers E, Peterson M, Lane JM (2003) Six minute walk test: a new powerful predictor of functional dysfunction in osteoporotic patients with and without vertebral fractures (abstract). J Bone Min Res (in press)

60.

Lindsay R, Hart DM, Forrest C, Baird C (1980) Prevention of spinal osteoporosis in oophorectomised women. Lancet 2:1151–1154PubMed

61.

Lindsay R, Silverman SL, Cooper C, Hanley DA, et al (2002) Risk of new vertebral fracture in the year following fracture. JAMA 17:285:320–323

62.

Liu G, Peacock M, Eilam O, Dorulla G, Braunstein E, Johnston CC (1997) Effect of osteoarthritis in the lumbar spine and hip on bone mineral density and diagnosis of osteoporosis in elderly men and women. Osteoporos Int 7:564–569PubMed

63.

Lofman O, Larsson L, Toss G (2000) Bone mineral density in diagnosis of osteoporosis: reference population, definition of peak bone mass, and measured site determine prevalence. J Clin Densitom 3:177–186

64.

Looker AC, Johnston CC Jr, Wahner HW, et al Prevalence of low femoral bone density in older US women from NHANES III (1995) J Bone Miner Res 10:796–802PubMed

65.

Luckey MM, Gilchrist N, Bone HG, et al (2003) Therapeutic equivalence of alendronate 35 milligrams once weekly and 5 milligrams daily in the prevention of postmenopausal osteoporosis. Obstet Gynecol 101:711–721CrossRefPubMed

66.

Marshall D, Johnell O, Wedel H (1996) Meta-analysis of how well measures of bone density predict occurrence of osteoporotic fractures. BMJ 312:1254–1259PubMed

67.

Matthis C, Weber U, O’Neill TW, Raspe H (1998) Health impact associated with vertebral deformities: results from the European Vertebral Osteoporosis Study (EVOS). Osteoporos Int 8:364–372CrossRefPubMed

68.

Melton LJ 3rd, Chrischilles EA, Cooper C, Lane AW, Riggs BL (1992) Perspective. How many women have osteoporosis? J Bone Miner Res 7:1005–1010PubMed

69.

Melton LJ 3rd, Atkinson EJ, Cooper C, O’Fallon WM, Riggs BL (1999) Vertebral fractures predict subsequent fractures. Osteoporos Int 10:214–221CrossRefPubMed

70.

Miller PD (2001) New possibilities for diagnosis and treatment of osteoporosis. Int J Fertil Womens Med 46:215–221PubMed

71.

Moro M, Hecker AT, Bouxsein ML, Myers ER (1995) Failure load of thoracic vertebrae correlates with lumbar bone mineral density measured by DXA. Calcif Tissue Int 56:206–209PubMed

72.

Nakajima A, Shimoji N, Shiomi K, et al (2002) Mechanisms for the enhancement of fracture healing in rats treated with intermittent low-dose human parathyroid hormone (1–34). J Bone Miner Res 17:2038–2047PubMed

73.

Neer RM, Arnaud CD, Zanchetta JR, et al (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441PubMed

74.

Neuner JM, Zimmer JK, Hamel MB (2003) Diagnosis and treatment of osteoporosis in patients with vertebral compression fractures. J Am Geriatr Soc 51:483–491PubMed

75.

Nordin BE, Morris HA (1989) The calcium deficiency model for osteoporosis. Nutr Rev 47:65–72PubMed

76.

O’Gradaigh D, Debiram I, Love S, Richards HK, Compston JE (2003) A prospective study of discordance in diagnosis of osteoporosis using spine and proximal femur bone densitometry. Osteoporos Int 14:13–18PubMed

77.

Okazaki K, Jingushi S, Ikenoue T, Urabe K, Sakai H, Iwamoto Y (2003) Expression of parathyroid hormone-related peptide and insulin-like growth factor I during rat fracture healing. J Orthop Res 21:511–520CrossRefPubMed

78.

Orwoll E, Ettinger M, Weiss S, et al (2000) Alendronate for the treatment of osteoporosis in men. N Engl J Med 343:604–610PubMed

79.

Osteoporosis prevention, diagnosis, and therapy (2000) NIH Consensus Statement 17:1–45

80.

Owens JM, Fuller K, Chambers TJ (1997) Osteoclast activation: potent inhibition by the bisphosphonate alendronate through a nonresorptive mechanism. J Cell Physiol 172:79–86CrossRefPubMed

81.

Paganini-Hill A, Chao A, Ross RK, Henderson BE (1991) Exercise and other factors in the prevention of hip fracture: the Leisure World study. Epidemiology 2:16–25PubMed

82.

Park J, Ries J, Gelse K, et al (2003) Bone regeneration in critical size defects by cell-mediated BMP-2 gene transfer: a comparison of adenoviral vectors and liposomes. Gene Ther 10:1089–1098CrossRefPubMed

83.

Pasquini GM, Davey RA, Ho PW, et al (2002) Local secretion of parathyroid hormone-related protein by an osteoblastic osteosarcoma (UMR 106–01) cell line results in growth inhibition. Bone 31:598–605CrossRefPubMed

84.

Peter CP, Cook WO, Nunamaker DM, Provost MT, Seedor JG, Rodan GA (1996) Effect of alendronate on fracture healing and bone remodeling in dogs. J Orthop Res 14:74–79PubMed

85.

Rea JA, Chen MB, Li J, et al (2000) Morphometric X-ray absorptiometry and morphometric radiography of the spine: a comparison of prevalent vertebral deformity identification. J Bone Miner Res 15:564–574PubMed

86.

Rea JA, Chen MB, Li J, et al (2001) Vertebral morphometry: a comparison of long-term precision of morphometric X-ray absorptiometry and morphometric radiography in normal and osteoporotic subjects. Osteoporos Int 12:158–166CrossRefPubMed

87.

Recker RR, Hinders S, Davies KM, et al (1996) Correcting calcium nutritional deficiency prevents spine fractures in elderly women. J Bone Miner Res 11:1961–1966PubMed

88.

Riew KD, Wright NM, Cheng S, Avioli LV, Lou J (1998) Induction of bone formation using a recombinant adenoviral vector carrying the human BMP-2 gene in a rabbit spinal fusion model. Calcif Tissue Int 63:357–360

89.

Ross PD (1996) Osteoporosis. Frequency, consequences, and risk factors. Arch Intern Med 156:1399–1411PubMed

90.

Saag KG, Emkey R, Schnitzer TJ, et al (1998) Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 339:292–299CrossRefPubMed

91.

Sahota O(2000) Osteoporosis and the role of vitamin D and calcium-vitamin D deficiency, vitamin D insufficiency, and vitamin D sufficiency. Age Ageing 29:301–304CrossRefPubMed

92.

Sarkar S, Mitlak BH, Wong M, Stock JL, Black DM, Harper KD (2002) Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res 17:1–10PubMed

93.

Schousboe JT, DeBold CR, Bowles C, Glickstein S, Rubino RK (2002) Prevalence of vertebral compression fracture deformity by X-ray absorptiometry of lateral thoracic and lumbar spines in a population referred for bone densitometry. J Clin Densitom 5:239–246PubMed

94.

Shields AT, Chesnut CH 3rd (2001) Diagnosis of postmenopausal osteoporosis: reviews in endocrine and metabolic disorders. Rev Endocr Metab Disord 2:23–33CrossRefPubMed

95.

Simkin A, Ayalon J, Leichter I (1987) Increased trabecular bone density due to bone-loading exercises in postmenopausal osteoporotic women. Calcif Tissue Int 40:59–63PubMed

96.

Stephenson J (2003) FDA orders estrogen safety warnings: agency offers guidance for HRT use. JAMA 289:537–538CrossRefPubMed

97.

Strocchi R, Orsini G, Iezzi G, et al (2002) Bone regeneration with calcium sulfate: evidence for increased angiogenesis in rabbits. J Oral Implantol 28:273–278PubMed

98.

Tinetti ME, Baker DI, Garrett PA, Gottschalk M, Koch ML, Horwitz RI (1993) Yale FICSIT: risk factor abatement strategy for fall prevention. J Am Geriatr Soc 41:315–320PubMed

99.

Varady P, Li JZ, Alden TD, Kallmes DF, Williams MB, Helm GA (2002) CT and radionuclide study of BMP-2 gene therapy-induced bone formation. Acad Radiol 9:632–637PubMed

100.

Wolf SL, Barnhart HX, Kutner NG, McNeely E, Coogler C, Xu T (1996) Reducing frailty and falls in older persons: an investigation of Tai Chi and computerized balance training. Atlanta FICSIT Group. Frailty and injuries: cooperative studies of intervention techniques. J Am Geriatr Soc 44:489–497PubMed

101.

Wu G (2002) Evaluation of the effectiveness of Tai Chi for improving balance and preventing falls in the older population — a review. J Am Geriatr Soc 50:746–754CrossRefPubMed

102.

Zerath E, Holy X, Noel B, Malouvier A, Hott M, Marie PJ (1998) Effects of BMP-2 on osteoblastic cells and on skeletal growth and bone formation in unloaded rats. Growth Horm IGF Res 8:141–149

Title: The aging spine: new technologies and therapeutics for the osteoporotic spine
Authors: Joseph M. Lane
Michael J. Gardner
Julie T. Lin
Marjolein C. van der Meulen
Elizabeth Myers
Publication date: 01-10-2003
Publisher: Springer-Verlag
Published in: European Spine Journal / Issue Special Issue 2/2003
Print ISSN: 0940-6719
Electronic ISSN: 1432-0932
DOI: https://doi.org/10.1007/s00586-003-0636-6

At a glance: The STEP trials

Springer Medicine

The aging spine: new technologies and therapeutics for the osteoporotic spine

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Special Issue 2/2003

Bisphosphonates in osteoporosis

Principles of management of osteometabolic disorders affecting the aging spine

Medical treatment of vertebral osteoporosis

Posterior approach to the degenerative cervical spine

The conservative surgical treatment of lumbar spinal stenosis in the elderly

Recognizing and reporting osteoporotic vertebral fractures